Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $105
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Buy' rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $101 to $105.
July 19, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a 'Buy' rating on Edwards Lifesciences and raises the price target from $101 to $105.
The 'Buy' rating maintained by Truist Securities and the increase in price target from $101 to $105 indicates a positive outlook for Edwards Lifesciences. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100